文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

百毒解断颗粒治疗中度COVID-19:开放标签随机对照试验方案

Baidu Jieduan granules, traditional Chinese medicine, in the treatment of moderate coronavirus disease-2019 (COVID-19): study protocol for an open-label, randomized controlled clinical trial.
PubMed 文献 · Trials · 2021-07-22

本研究为多中心、开放标签、随机对照试验,计划纳入300例中度COVID-19患者,按1:1随机分为治疗组和对照组,所有患者均接受标准治疗。试验组加用百毒解断颗粒每日两次、连用14天,主要结局为症状(发热、乏力、咳嗽)恢复率,并全程监测不良事件,旨在评估该中药的疗效与安全性。

要点

  • 百毒解断颗粒每日两次、连用14天,联合标准治疗用于中度COVID-19。
  • 主要结局为发热、乏力、咳嗽的症状恢复率,于第3、5、7、14天评估。
  • 试验为多中心、开放标签、随机对照设计,计划纳入300例患者。

核心结论

  • 该试验旨在为百毒解断颗粒治疗中度COVID-19的疗效与安全性提供高质量临床证据。

研究设计与样本

  • 多中心、开放标签、随机对照试验,计划纳入300例COVID-19患者,按1:1随机分为治疗组与对照组。
  • 所有患者同时接受标准治疗,试验组加用百毒解断颗粒每日两次、连用14天。
  • 于基线及治疗开始后第3、5、7、14天评估结局指标。

关键数值与推荐

  • 主要结局为症状(发热、乏力、咳嗽)恢复率。
  • 不良事件在整个试验期间监测。
  • 试验注册号ChiCTR2000029869,注册日期2020年2月15日。

临床怎么用

  • 若试验证实有效,可为中度COVID-19在标准治疗基础上加用百毒解断颗粒提供依据。

局限性

  • 开放标签设计可能引入偏倚。
  • 研究方案阶段,尚未报告疗效与安全性结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, coronavirus disease-2019 (COVID-19) is continuously and rapidly circulating, resulting in serious and extensive effects on human health. Due to the absence of antiviral medicine for COVID-19 thus far, there is a desperate need to develop effective medicine. Traditional Chinese medicine (TCM) has been widely applied in the treatment of epidemic diseases in China, with the aim of achieving clinical efficacy and decreasing the use of antibiotics and glucocorticoids. The aim of this study was to evaluate the efficacy and safety of Baidu Jieduan granules in treating COVID-19. METHODS/DESIGN: This multicentre, open-label, randomized controlled trial will be conducted in 300 patients with COVID-19. The patients will be randomly (1:1) divided into a treatment group and a control group. All patients will receive standard therapy at the same time. Patients in the experimental group will receive Baidu Jieduan granule treatment twice a day for 14 days. The outcomes will be assessed at baseline and at 3, 5, 7 and 14 days after treatment initiation. The primary outcome will be the rate of symptom (fever, fatigue and coughing) recovery. Adverse events (AEs) will be monitored throughout the trial. DISCUSSION: The study will provide high-quality clinical evidence to support the efficacy and safety of Baidu Jieduan granules in the treatment of moderate COVID-19, and enrich the theory and practice of TCM in treating COVID-19. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000029869 . Registered on 15 February 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang W, Xie Q, Xu X, et al. Baidu Jieduan granules, traditional Chinese medicine, in the treatment of moderate coronavirus disease-2019 (COVID-19): study protocol for an open-label, randomized controlled clinical trial. Trials. 2021. PMID: 34294144. doi:10.1186/s13063-021-05418-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。